Want to see IN:ONESOURCE full AI Analyst Report?
ONESOURCE Stock Chart & Stats
₹1653.40
₹35.00(2.12%)
At close: 4:00 PM EDT
₹1653.40
₹35.00(2.12%)
Day’s Range― - ―
52-Week Range₹1,075.00 - ₹1,924.00
Previous CloseN/A
Volume717.16K
Average Volume (3M)3.94K
Market Cap
₹175.79B
Enterprise Value₹222.64K
Total Cash (Recent Filing)₹1.80B
Total Debt (Recent Filing)₹12.95B
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.53
Shares Outstanding114,669,990
10 Day Avg. Volume3,856
30 Day Avg. Volume3,937
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.89
Price to Sales (P/S)11.87
P/FCF Ratio-24.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)36.13
Revenue Forecast (FY)₹22.53B
Bulls Say, Bears Say
Bulls Say
Strong Revenue ExpansionThe sharp FY2026 top-line acceleration indicates meaningful growth in demand or business activity. Sustaining this expansion could improve operating scale over the next several quarters, although profitability must recover for growth to create durable value.
Substantial Equity BaseA sizeable equity cushion provides financial resilience and reduces reliance on debt financing compared with a highly leveraged structure. This can give the company greater flexibility to fund operations while it works to restore profitability.
Manageable Overall LeverageAlthough debt is rising, leverage remains described as manageable relative to the company’s equity base. This limits immediate balance-sheet strain and provides some capacity to absorb temporary losses, provided borrowing does not continue escalating.
Bears Say
Severe Profitability DeteriorationThe shift into a large loss shows that recent revenue growth is not translating into earnings. Sustained margin pressure or elevated costs could weaken reinvestment capacity and delay the path to self-funded expansion.
Persistent Cash BurnOngoing negative operating and free cash flow means the business is funding operations or investment through its balance sheet rather than internally generated cash. Persistent burn can increase financing needs and reduce strategic flexibility.
Rising Debt Amid LossesHigher debt alongside worsening earnings creates a less favorable financial trajectory. If losses and cash burn persist, additional borrowing could raise financing costs, constrain investment choices, and erode the current balance-sheet cushion.
OneSource Specialty Pharma Limited News
ONESOURCE FAQ
What was OneSource Specialty Pharma Limited’s price range in the past 12 months?
OneSource Specialty Pharma Limited lowest stock price was ₹1075.00 and its highest was ₹1924.00 in the past 12 months.
What is OneSource Specialty Pharma Limited’s market cap?
OneSource Specialty Pharma Limited’s market cap is ₹175.79B.
When is OneSource Specialty Pharma Limited’s upcoming earnings report date?
OneSource Specialty Pharma Limited’s upcoming earnings report date is Nov 17, 2026 which is in 82 days.
How were OneSource Specialty Pharma Limited’s earnings last quarter?
OneSource Specialty Pharma Limited released its earnings results on Jul 24, 2026. The company reported ₹2.6 earnings per share for the quarter, missing the consensus estimate of ₹5.3 by -₹2.7.
Is OneSource Specialty Pharma Limited overvalued?
According to Wall Street analysts OneSource Specialty Pharma Limited’s price is currently Overvalued.
Does OneSource Specialty Pharma Limited pay dividends?
OneSource Specialty Pharma Limited does not currently pay dividends.
What is OneSource Specialty Pharma Limited’s EPS estimate?
OneSource Specialty Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OneSource Specialty Pharma Limited have?
OneSource Specialty Pharma Limited has 114,669,990 shares outstanding.
What happened to OneSource Specialty Pharma Limited’s price movement after its last earnings report?
OneSource Specialty Pharma Limited reported an EPS of ₹2.6 in its last earnings report, missing expectations of ₹5.3. Following the earnings report the stock price went down -0.024%.
Which hedge fund is a major shareholder of OneSource Specialty Pharma Limited?
Currently, no hedge funds are holding shares in IN:ONESOURCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts its operations internationally, with a footprint in India, Ireland, and the United States. It delivers comprehensive contract development and manufacturing (CDMO) services for biologics, encompassing all phases from preclinical and clinical development to commercial-scale supply. Its offerings extend to integrated drug-device systems such as pre-filled syringes, various pen injectors (including dial, push, and pull-push types for both variable and fixed doses), and autoinjectors. Furthermore, OneSource Specialty Pharma manufactures sterile injectable drugs and soft gelatin capsules, and provides specialized biologics solutions tailored for microbial and mammalian cell-line biopharmaceuticals, as well as for cell, gene, and RNA therapies. Established in 2007, the company, headquartered in Bengaluru, India, was formerly known as Stelis Biopharma Limited until its rebranding in February 2024.
Technical Analysis
Biocon Limited
―
Blue Jet Healthcare Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Syngene International Ltd.
―